Experimental benznidazole encephalopathy: I. Clinical-neurological alterations.
Benznidazole (N-benzyl-2-nitro-1-imidazoleacetamide) is an antiprotozoan agent of the nitroimidazole group used extensively in South America to treat Chagas' disease. In humans, its most important side effect is peripheral polyneuropathy, the frequency of which is dose related. To evaluate this effect, we administered benznidazole to adult, male, mongrel dogs at doses ranging from 5 to 40 mg/kg/day (0.5 to 4 times the dose used to treat chagasic patients). Subsequent neurological examination revealed apathy, ataxia, spastic tetraplegia with hyperreflexia of stretching reflexes, balance disorders and asymmetrical gait. These alterations appeared earlier and were more intense at the higher doses. Drug withdrawal also left dose- and time-dependent sequelae like ataxia, hypertonia, hyperreflexia and alterations of balance. No peripheral neuropathy was detected. The present findings suggest that a careful reevaluation of the side effects of benznidazole in humans is necessary.
Flores-Vieira
C L
CL
Department of Neurology, Psychiatry and Medical Psychology, University of São Paulo, Ribeirão Preto, Brazil.
Barreira
A A
AA
D000818:Animals; D001259:Ataxia / Q000139:chemically induced; D001927:Brain Diseases / Q000139:chemically induced* / Q000503:physiopathology; D003391:Cranial Nerves / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009498:Neurotoxins; D009593:Nitroimidazoles / Q000633:toxicity*; D011187:Posture; D011782:Quadriplegia / Q000139:chemically induced; D012018:Reflex / Q000187:drug effects; D012026:Reflex, Stretch / Q000187:drug effects; D014344:Trypanocidal Agents / Q000633:toxicity*
D009498:Neurotoxins; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; C009999:benzonidazole